Study of Diquafosol Tetrasodium Ophthalmic Solution in Subjects With Dry Eye Disease
Launched by MERCK SHARP & DOHME LLC · Nov 24, 2006
Trial Information
Current as of June 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • best corrected visual acuity in both eyes of at least +0.7
- • six-month documented history of dry eye disease
- • as least mild severity in 1 of the 5 dry eye symptoms
- • corneal fluorescein staining of greater than or equal to 3 and less than or equal to 6 (out of 15)
- Exclusion Criteria:
- • permanent conjunctival goblet cell loss or scarring conditions
- • ongoing contact lens wear
- • current topical ophthalmic medication use
About Merck Sharp & Dohme Llc
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., is a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and vaccines that address unmet medical needs. With a strong focus on research and development, Merck Sharp & Dohme leverages advanced science and technology to enhance patient outcomes across various therapeutic areas, including oncology, infectious diseases, and cardiovascular health. Committed to ethical practices and regulatory compliance, the company actively engages in clinical trials to advance medical knowledge and improve health care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials